Hot Stocks: Brokerage view on Prestige Estates, JB Pharma, Uno Minda and Jyothy Labs

Brokerage firm Citigroup maintained a buy rating on Prestige Estates while Jefferies recommended a buy on JB Pharma.

ICICI Securities has a buy rating on Jyothy Labs and Elara Capital recommended a buy on Uno Minda.

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

Citigroup on Prestige Estates: Buy| Target Rs 982
Citigroup maintained a buy rating on Prestige Estates but raised the target price to Rs 982 from Rs 693 earlier.

The 2QFY24 results were very strong pre-sales and execution. The net debt increased in 2Q but not a cause of concern as of now.

Prestige continues to scale up well, which should sustain valuations.

Jefferies on JB Pharma: Buy| Target Rs 1680
Jefferies maintained a buy rating on JB Pharma post Q2 results but raised the target price to Rs 1680 from Rs 1555.The Q2 results beat expectations on higher gross margins/lower SG&A spend. FY24 Ebitda margins were seen at the upper end of 25-27% (ex-ESOP cost range).

India and CDMO are likely to account for 75-80% of sales in three years.

Elara Capital on Uno Minda: Buy| Target Rs 720
Elara Capital maintained a buy rating on Uno Minda post Q2 results with a target price of Rs 720. Commissioning of new alloy wheels, switches, and lighting capacity to aid incremental revenue growth.

But the margin may be range-bound on fixed cost from the ramp-up of new capacity. Rising EV focus and kit value for EV/ICE to aid OEM growth outperformance.

The brokerage firm expects 18% revenue CAGR in FY23-26E, outperforming 2W and PV OEM CAGR of ~8%. It expects an EPS CAGR of 23% in FY23-26E.

“We are positive on UNOMNDA’s strong execution capability as it benefits from four LACE megatrends,” said the note.

ICICI Securities on Jyothy Labs: Buy| Target Rs 465
ICICI Securities maintained a buy rating on Jyothy Labs post Q2 results but raised the target price to Rs 465 from Rs 380 earlier.

Jyothy Labs continued to report double-digit revenue growth of 11% YoY (with double-digit growth in 2Y, 3Y, 4Y CAGR as well) with volume growth of 9% (outperforming peers) driven by focus on volume growth led by distribution expansion into new geographies.

It reported double-digit revenue growth across segments, except for household insecticides which were impacted due to lower rainfall.

(You can now subscribe to our ETMarkets WhatsApp channel)

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)

(What’s moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

Top Trending Stocks: Sensex Today Live, SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Secular Times is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – seculartimes.com. The content will be deleted within 24 hours.

Leave a Comment